Alport syndrome

News

Bayer takes Alport syndrome drug into phase 2

Bayer has started a phase 2a trial of an antibody that it hopes could provide a targeted, potentially disease-modifying therapy for Alport syndrome.

News

Ardelyx’s-ambition-to-revolutionise-kidney-treatment

FDA advisors unconvinced by Reata's kidney disease drug

An FDA advisory committee has delivered a blow to Reata Pharma, after voting unanimously that the drugmaker's data on bardoxolone – a drug for kidney disease – did not show it is effective.

News

GSK showcases positive data with lung cancer drugs at WCLC

New data at WCLC26 could push GSK's ROS1+ NSCLC drug Jideytro into the first-line setting, while B7-H3-targeted ADC ris-rez extends survival in SCLC.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks